Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tectonic Therapeutic (TECX) Current Deferred Revenue (2019 - 2022)

Tectonic Therapeutic (TECX) has 4 years of Current Deferred Revenue data on record, last reported at $51000.0 in Q3 2022.

  • On a quarterly basis, Current Deferred Revenue fell 80.83% to $51000.0 in Q3 2022 year-over-year; TTM through Sep 2022 was $51000.0, a 80.83% decrease, with the full-year FY2021 number at $262000.0, up 9.62% from a year prior.
  • Current Deferred Revenue reached $51000.0 in Q3 2022 per TECX's latest filing, down from $183000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for TECX hit a ceiling of $266000.0 in Q3 2021 and a floor of $51000.0 in Q3 2022.
  • A 4-year average of $215200.0 and a median of $227500.0 in 2020 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: rose 23.15% in 2021, then tumbled 80.83% in 2022.
  • Tracing TECX's Current Deferred Revenue over 4 years: stood at $214000.0 in 2019, then grew by 11.68% to $239000.0 in 2020, then rose by 9.62% to $262000.0 in 2021, then plummeted by 80.53% to $51000.0 in 2022.
  • Business Quant data shows Current Deferred Revenue for TECX at $51000.0 in Q3 2022, $183000.0 in Q2 2022, and $214000.0 in Q1 2022.